Brickell Z Score

BBI
 Stock
  

USD 4.41  0.43  10.80%   

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Continue to Brickell Biotech Piotroski F Score and Brickell Biotech Valuation analysis.
  
Refresh
Brickell Biotech Working Capital is most likely to decrease significantly in the upcoming years. The last year's value of Working Capital was reported at 24.79 Million. Brickell Biotech Gross Profit is most likely to decrease significantly in the upcoming years. The last year's value of Gross Profit was reported at 404,000. The current Interest Expense is estimated to increase to about 63.7 K, while Consolidated Income is projected to decrease to (40.5 M).

Brickell Z Score Analysis

Brickell Biotech's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2019 2020 2021 2022 (projected)
Revenues USD7.92 M1.82 M404 K414.63 K
Revenues7.92 M1.82 M404 K414.63 K
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Brickell Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Brickell Biotech is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Brickell Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brickell Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brickell Biotech's interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition
In accordance with the company's disclosures, Brickell Biotech has a Z Score of 0.0. This is 100.0% lower than that of the sector and 100.0% lower than that of the Z Score industry. The z score for all United States stocks is 100.0% higher than that of the company.

Brickell Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brickell Biotech's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brickell Biotech could also be used in its relative valuation, which is a method of valuing Brickell Biotech by comparing valuation metrics of similar companies.
Brickell Biotech is currently under evaluation in z score category among related companies.

Brickell Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brickell Biotech from analyzing Brickell Biotech's financial statements. These drivers represent accounts that assess Brickell Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brickell Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(122.58 K)(175.13 K)(541.8 K)(1.59 M)(1.83 M)(1.88 M)
Revenue Per Employee198.51 K186.74 K54.07 K527.8 K475.02 K512.52 K
Average Assets58.08 M45.63 M34.66 M25.13 M30.46 M39.21 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings before Tax(12.96 M)(9.24 M)(23.88 M)(20.91 M)(39.47 M)(40.51 M)
Average Equity45.92 M23.07 M27.82 M17.91 M24.09 M32.33 M
Enterprise Value12.67 M13.45 M4.59 M22.04 M4.97 M5.1 M
Free Cash Flow(8.68 M)3.96 M(35.99 M)(20.06 M)(36.18 M)(37.14 M)
Invested Capital37.84 M(15.21 M)488 K(2.4 M)(1.98 M)(2.03 M)
Invested Capital Average32.37 M28.85 M20.09 M(1.32 M)(2.55 M)(2.62 M)
Market Capitalization23.07 M25.74 M11.72 M41.77 M26.33 M27.03 M
Tangible Asset Value79.79 M8.31 M18.14 M33.63 M29.72 M36.69 M
Working Capital59.4 M(11.82 M)7.47 M27.18 M24.79 M28.97 M

Brickell Biotech Institutional Holders

Institutional Holdings refers to the ownership stake in Brickell Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Brickell Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Brickell Biotech's value.
Security TypeSharesValue
Vanguard Group IncCommon Shares3.1 M832 K
Telemetry Investments LlcCommon Shares1.9 M510 K
Renaissance Technologies LlcCommon Shares1.4 M380 K
Palisade Capital Management LlcCommon Shares970.5 K260 K
Geode Capital Management LlcCommon Shares627.3 K167 K
Blackrock IncCommon Shares215.7 K57 K
Citadel Advisors LlcCommon Shares137.4 K37 K

Brickell Fundamentals

About Brickell Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Brickell Biotech Investors Sentiment

The influence of Brickell Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brickell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Brickell Biotech's public news can be used to forecast risks associated with investment in Brickell. The trend in average sentiment can be used to explain how an investor holding Brickell can time the market purely based on public headlines and social activities around Brickell Biotech. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Brickell Biotech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brickell Biotech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brickell Biotech's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Brickell Biotech.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.

Current Sentiment - BBI

Brickell Biotech Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brickell Biotech. What is your opinion about investing in Brickell Biotech? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Brickell Biotech Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brickell Biotech Piotroski F Score and Brickell Biotech Valuation analysis. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
11.7 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.